CelLBxHealth plc Stock

CLBX

GB0034330679

Advanced Medical Equipment & Technology

Market Closed - London S.E. Other stock markets 19:35:29 03/07/2026 +04			5-day change	1st Jan Change
1.500 ^GBX	0.00%		-1.64%	+36.36%

06-22	CelLBxHealth guides for higher 2026 revenue but loss widens	AN
06-22	WINNERS & LOSERS: eEnergy cuts revenue, adjusted Ebitda forecasts	AN

Latest news : CelLBxHealth plc

06-22	CelLBxHealth guides for higher 2026 revenue but loss widens	AN
06-22	WINNERS & LOSERS: eEnergy cuts revenue, adjusted Ebitda forecasts	AN
05-29	WINNERS & LOSERS: CelLBxHealth jumps on AstraZeneca partnership	AN
05-29	CelLBxHealth shares jump on partnership with AstraZeneca	AN
05-29	FTSE 100 climbs as US-Iran deal draws closer	AN
05-29	Cellbxhealth Partners with AstraZeneca to Support Drug Development Research	MT
05-29	CelLBxHealth PLC Enters Master Services Agreement With AstraZeneca PLC	CI
05-29	CellBxHealth enters master services agreement with AstraZeneca	RE
05-22	WINNERS & LOSERS: Creo Medical jumps; Hercules resumes trading	AN
05-18	UK's CelLBxHealth to Provide Technology for Two Cancer Studies in US	MT
05-11	CelLBxHealth shares jump on forecast for 50% revenue growth in 2026	AN
05-11	CelLBxHealth plc Provides Revenue Guidance for the Year 2026	CI
05-11	WINNERS & LOSERS: Asos sells Lichfield centre; CelLBxHealth revenue up	AN

More news

Last Transcript: CelLBxHealth plc

CelLBxHealth plc - Special Call

12-02

More transcripts

Analysts' recommendations: CelLBxHealth plc

16/10/25	Angle names Peter Collins as interim CEO	AN
28/05/25	RBC cuts National Grid; Citigroup cuts South32	AN
23/01/25	HSBC raises FirstGroup, Goldman cuts Ithaca	AN
14/09/23	JPMorgan ups Rio Tinto; Redburn likes Carnival	AN
24/01/22	Berenberg Initiates Angle With Buy Rating, Sets PT	MT

More recommendations

Press Releases: CelLBxHealth plc

30/10/25	ANGLE plc - Change of Name	AQ
10/09/25	Presentation slides 9 September 2025: Interim Results for the six months ended 30 June 2025	PU
11/06/25	ANGLE PLC - PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer	AQ
10/06/25	ANGLE : Sustainability and ESG strategy overview 2024	PU
06/06/25	ANGLE : Annual Report December 2024	PU

More press releases

News in other languages: CelLBxHealth plc

20/04/23	Avis d'analystes du jour : ASML, SAP, Euronext, OVH, Barry Callebaut, Sika, Lindt...
20/04/23	Panne de volatilité ?

More news

Managers and Directors: CelLBxHealth plc

Manager	Title	Age	Since
Peter Collins CEO	Chief Executive Officer	68	16/10/2025
Sinéad Armstrong DFI	Director of Finance/CFO	-	01/01/1999
Karen Miller CTO	Chief Tech/Sci/R&D Officer	-	05/06/2023

Director	Title	Age	Since
Jan Groen CHM	Chairman	67	22/05/2023
Peter Collins BRD	Director/Board Member	68	12/01/2026
Klaas de Boer BRD	Director/Board Member	61	12/01/2026

More insiders

Medical Diagnostic & Testing Equipment

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELLBXHEALTH PLC	0.00%	-1.64%	-76.92%	-88.24%	22.76M
SARTORIUS AG	-1.95%	+1.16%	+3.00%	-28.72%	16.36B
INNER MONGOLIA FURUI MEDICAL SCIENCE CO., LTD.	+5.89%	+23.51%	+44.56%	+95.19%	1.78B
QUIDELORTHO CORPORATION	+0.39%	+32.34%	-39.55%	-78.08%	1.24B
ECKERT & ZIEGLER SE	+0.06%	+3.85%	-28.59%	+34.44%	1.14B
CONTEC MEDICAL SYSTEMS CO.,LTD	+1.31%	+4.95%	-25.86%	-53.39%	640M
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.	+0.21%	+3.42%	-38.49%	-58.09%	582M
VAREX IMAGING CORPORATION	-0.66%	+3.11%	+20.57%	-55.49%	447M
REVENIO GROUP OYJ	+1.79%	+0.16%	-55.37%	-60.09%	382M
CELLAVISION AB	+2.52%	+7.65%	-20.35%	-17.75%	362M
Average	+0.96%	+6.69%	-21.70%	-31.02%	2.3B
Weighted average by Cap.	-0.81%	+4.50%	-0.57%	-21.00%

See all sector performances

Cellbxhealth PLC, formerly ANGLE plc, is a global precision circulating tumor cell (CTC) intelligence company specializing in innovative circulating tumor cell solutions for use in research, drug development and clinical oncology. The product portfolio comprises the Parsortix platform with associated consumables and assays. Its Parsortix platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology. Its Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.

Employees

119

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
03/07/26	GBX 1.500	0.00%	716,727
02/07/26	GBX 1.500	-1.64%	973,749
01/07/26	GBX 1.525	0.00%	161,681
30/06/26	GBX 1.525	0.00%	685,230
29/06/26	GBX 1.525	0.00%	581,974

Delayed Quote London S.E.

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0150GBP

Average target price

0.0400GBP

Spread / Average Target

+166.67%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Cap	17.05M 22.76M 19.9M 18.29M 32.33M 2.17B 32.82M 220M 85.35M 1.07B 85.44M 83.61M 3.67B	P/E 2025 *	-0.26x	P/E 2026 *	-0.64x
Enterprise Value	9.75M 13.01M 11.38M 10.46M 18.49M 1.24B 18.77M 126M 48.8M 609M 48.85M 47.8M 2.1B	EV / Sales 2025 *	0.94x	EV / Sales 2026 *	0.71x
Free-Float	94.31%	Yield 2025 *	-	Yield 2026 *	-

1 week	-1.64%
Current month	-1.64%
1 month	-16.67%
3 months	+66.67%
6 months	+36.36%
Current year	+36.36%

1 week	1.41	1.65
1 month	1.3	2
Current year	0.85	2.8
1 year	0.85	8
3 years	0.85	37.4
5 years	0.85	163.75
10 years	0.85	163.75

Date	Insider	Type	Main position	Quantity	% Market Cap.
12-19	Peter Collins	Buy	Chief Executive Officer	5,000,000	1.5497%
12-19	Jan Groen	Buy	Chairman	5,000,000	1.5497%
12-19	Sinéad Armstrong	Buy	Chief Financial Officer	2,500,000	0.7749%

	2025 *	2026 *
Net sales	10.35M 13.83M 12.09M 11.11M 19.64M 1.32B 19.94M 133M 51.84M 647M 51.9M 50.79M 2.23B	21.65M 28.91M 25.27M 23.23M 41.06M 2.75B 41.69M 279M 108M 1.35B 109M 106M 4.66B
Net income	-16.35M -21.83M -19.09M -17.54M -31.01M -2.08B -31.48M -211M -81.86M -1.02B -81.95M -80.19M -3.52B	-8.55M -11.42M -9.98M -9.17M -16.22M -1.09B -16.46M -110M -42.81M -534M -42.86M -41.94M -1.84B
Net Debt	-7.3M -9.75M -8.52M -7.83M -13.85M -928M -14.06M -94.02M -36.55M -456M -36.59M -35.81M -1.57B	-1.6M -2.14M -1.87M -1.72M -3.03M -203M -3.08M -20.61M -8.01M -100M -8.02M -7.85M -345M

CelLBxHealth plc Stock

Stocks

CLBX

GB0034330679

Advanced Medical Equipment & Technology

Valuation: CelLBxHealth plc

Chart: CelLBxHealth plc

Latest news : CelLBxHealth plc

Last Transcript: CelLBxHealth plc

Analysts' recommendations: CelLBxHealth plc

Press Releases: CelLBxHealth plc

News in other languages: CelLBxHealth plc

Quotes and Performance

Course Extremes

Managers and Directors: CelLBxHealth plc

Latest insider transactions

Medical Diagnostic & Testing Equipment

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Annual profits - Rate of surprise